1 Result: CureVac
CureVac's Patent Litigation Moves to Virginia, Ambrx Biopharma Receives Overweight Rating, Legend Biotech Gets Price Target Boost
May 19th, 2023
CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachuset. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
October 29th, 2026
Treasury Sanctions Facilitators of DPRK IT Worker Fraud Targeting U.S. Businesses
October 28th, 2026Treasury Sanctions Rwandan Ministry of Defence and Financial Institution Supporting M23
October 28th, 2026October 26th, 2026FAA Releases Draft Design Standards for Vertical Flight Facilities
October 22nd, 2026
Member Login